RenovoRx, Inc. RNXT
We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration ("FDA")-cleared local drug-delivery device, targeting high unmet medical needs. Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
Our patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial , or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. Our novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $43.0K | — | — | — | — | — |
| Cost of revenue | $327.0K | $0 | — | — | — | — | — |
| Gross profit | $796.0K | $43.0K | — | — | — | — | — |
| R&D | $6.3M | $6.0M | $5.7M | $4.3M | $3.0M | $2.4M | — |
| SG&A | $7.0M | $5.0M | $5.7M | $5.6M | $2.6M | $818.0K | — |
| Total operating expenses | $13.3M | $11.0M | $11.4M | $9.9M | $5.7M | $3.2M | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M | -$3.2M | — |
| Interest expense | — | — | — | — | $834.0K | $587.0K | — |
| Pre-tax income | -$11.2M | -$8.8M | — | — | — | — | — |
| Income tax | $2.0K | — | — | — | — | — | — |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | -$6.3M | -$3.8M | — |
| EPS, basic | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 | — | — |
| EPS, diluted | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 | -1.72 | — |
| Shares, diluted (wtd. avg.) | 35.3M | 22.3M | 10.3M | 9.1M | 5.2M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.0M | $7.2M | $1.2M | $4.4M | $15.2M | $1.8M | — |
| Short-term investments | — | — | — | $2.0M | — | — | — |
| Receivables | $139.0K | $43.0K | — | — | — | — | — |
| Inventory | $189.0K | $0 | — | — | — | — | — |
| Total current assets | $7.9M | $7.8M | $1.5M | $7.3M | $16.3M | $1.9M | — |
| Property, plant and equipment | $12.0K | $12.0K | — | — | — | — | — |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M | $1.9M | — |
| Accounts payable | $799.0K | $586.0K | $561.0K | $534.0K | $525.0K | $162.0K | — |
| Total current liabilities | $2.0M | $1.9M | $1.2M | $1.1M | $938.0K | $4.1M | — |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938.0K | $4.1M | — |
| Retained earnings | -$61.4M | -$50.2M | -$41.4M | -$31.2M | -$21.3M | -$15.0M | — |
| Total equity | $5.4M | $4.5M | $3.0M | $6.2M | $15.3M | -$14.7M | -$10.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M | -$3.5M | — |
| Depreciation and amortisation | $2.0K | $0 | — | — | — | — | — |
| Stock-based compensation | $1.3M | $1.2M | $1.1M | $644.0K | $147.0K | $33.0K | — |
| Capital expenditure | $2.0K | $12.0K | — | — | — | — | — |
| Investing cash flow | -$2.0K | -$12.0K | $2.0M | -$2.0M | -$15.0K | — | — |
| Financing cash flow | $10.8M | $15.1M | $5.0M | $42.0K | $19.3M | $3.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-227256.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $43.0K | $1.1M |
| Gross profit | — | — | — | — | — | $43.0K | $796.0K |
| Net income | — | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |